BX-1000 is under clinical development by Baudax Bio and currently in Phase II for Anesthetic Effect. According to GlobalData, Phase II drugs for Anesthetic Effect have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BX-1000’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BX-1000 is under development for anaesthesia. The drug candidate is an intermediate-acting neuromuscular blocker. It is administered by intravenous bolus route.
Baudax Bio overview
Baudax Bio develops and commercializes novel products for acute care settings. The company’s lead product candidate meloxicam, an injection to treat osteoarthritis and rheumatoid arthritis. Baudax Bio is headquartered in Chester County, Pennsylvania, the US.
For a complete picture of BX-1000’s drug-specific PTSR and LoA scores, buy the report here.